Clinical Trials
PharmaEssentia trials
PharmaEssentia is committed to scientific excellence in its ongoing clinical research. We are deeply appreciative of the study sites, investigators, patients, caregivers, and clinicians who support our efforts through their participation.
Essential Thrombocythemia
SURPASS-ET
A Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of ropeginterferon alfa-2b-njft compared with an available treatment as second-line therapy for adults with essential thrombocythemia (ET). For more information, please visit www.clinicaltrials.gov (NCT04285086).
EXCEED-ET
A Phase 2b, single-arm, multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in adult patients with essential thrombocythemia (ET). For more information, please visit www.clinicaltrials.gov (NCT0548297).
Polycythemia Vera
ECLIPSE-PV
A Phase 3b, single-arm, multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adults with polycythemia vera (PV). Find more information by visiting www.clinicaltrials.gov:NCT05481151